AUTHOR=Seyed Jafari S. Morteza , Feldmeyer Laurence , Bossart Simon , Simon Dagmar , Schlapbach Christoph , Borradori Luca 

TITLE=Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

JOURNAL=Frontiers in Immunology

VOLUME=Volume 11 - 2020

YEAR=2021

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.611549

DOI=10.3389/fimmu.2020.611549

ISSN=1664-3224

ABSTRACT=Bullous pemphigoid (BP) is the most frequent autoimmune bullous dermatosis affecting predominantly the elderly. Omalizumab, a monoclonal antibody directed to IgE, showed an optimal effect in treatment of recalcitrant BP in recent studies. More recently, dupilumab, an interleukin (IL)-4 receptor alpha antagonist, was also reported as additional treatment. We describe patient with refractory BP, who showed a response only upon a combination of omalizumab and dupilumab.